Bioabsorbable stents offer an unproven but theoretically appealing means to address the deficiencies of current stent designs. Ideally, these stents would provide early postprocedural scaffolding support yet undergo a predictable process of reabsorption, thus removing the persistent stimulus for neointimal hyperplasia. Prototypes include polymeric formulations and magnesium-based absorbable metal stents. Current and future human trials will ascertain if bioabsorbable stents truly deliver a physiologic advantage in the treatment of peripheral occlusive disease.
Dotter CT, Judkins MP.Percutaneous transluminal treatment of arteriosclerotic obstruction. Radiology. 1965; 84: 631-643.
2.
Dotter CT, Krippaehne WW, Judkins MP.Transluminal recanalization and dilatation in atherosclerotic obstruction of femoral popliteal system. Am Surg. 1965;31: 453-459.
3.
Dotter CT.Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. Invest Radiol. 1969;4: 329-332.
Mintz GS, Popma JJ, Pichard AD, et al.Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94: 35-43.
6.
Palmaz JC, Richter GM, Noldge G, Kauffmann GW, Wenz W.[Intraluminal Palmaz stent implantation. The first clinical case report on a balloon-expanded vascular prosthesis]. Radiologe.1987;27: 560-563.
7.
Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH.Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102: 624-629.
8.
Steinhubl SR, Berger PB, Mann JT 3rd, et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288: 2411-2420.
9.
Hoffmann R, Mintz GS, Dussaillant GR, et al.Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94: 1247-1254.
10.
Grube E, Silber S, Hauptmann KE, et al.TAXUS I: sixand twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107: 38-42.
11.
Morice MC, Serruys PW, Sousa JE, et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346: 1773-1780.
12.
McFadden EP, Stabile E, Regar E, et al.Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364: 1519-1521.
13.
Spertus JA, Kettelkamp R, Vance C, et al.Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113: 2803-2809.
14.
Kotani J, Awata M, Nanto S, et al.Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47: 2108-2111.
15.
Yadav JS, Wholey MH, Kuntz RE, et al.Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351: 1493-1501.
16.
Willfort-Ehringer A, Ahmadi R, Gschwandtner ME, Haumer M, Lang W, Minar E.Single-center experience with carotid stent restenosis. J Endovasc Ther. 2002;9: 299-307.
17.
Schillinger M, Sabeti S, Loewe C, et al.Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354: 1879-1888.
18.
Mewissen MW.Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol. 2004;7: 2-5.
19.
Scheinert D, Scheinert S, Sax J, et al.Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45: 312-315.
20.
Duda SH, Bosiers M, Lammer J, et al.Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16(3): 331-338.
21.
Duda SH, Pusich B, Richter G, et al.Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106: 1505-1509.
22.
Tamai H, Igaki K, Kyo E, et al.Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102: 399-404.
23.
Biamino G, Schmidt A, Scheinert D.Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS study. J Endovasc Ther. 2005;12(Suppl I): 5-5.
24.
Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A.Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003;89: 651-656.
25.
Eggebrecht H, Rodermann J, Hunold P, et al.Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation. 2005;112: e303-e304.
26.
Peeters P, Bosiers M, Verbist J, Deloose K, Heublein B.Preliminary results after application of absorbable metal stents in patients with critical limb ischemia. J Endovasc Ther. 2005;12: 1-5.
